Log in

NASDAQ:EBIO - Eleven Biotherapeutics Stock Price, Forecast & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume15.58 million shs
Average Volume2.86 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Eleven Biotherapeutics, Inc, a biologic oncology company, focuses on the design and development of targeted protein therapeutics (TPTs). It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. The company's lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EBIO
CUSIPN/A
Phone617-871-9911

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableOptionable

Receive EBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for EBIO and its competitors with MarketBeat's FREE daily newsletter.


Eleven Biotherapeutics (NASDAQ:EBIO) Frequently Asked Questions

What is Eleven Biotherapeutics' stock symbol?

Eleven Biotherapeutics trades on the NASDAQ under the ticker symbol "EBIO."

How were Eleven Biotherapeutics' earnings last quarter?

Eleven Biotherapeutics (NASDAQ:EBIO) announced its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.11) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.03. View Eleven Biotherapeutics' Earnings History.

Has Eleven Biotherapeutics been receiving favorable news coverage?

Headlines about EBIO stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Eleven Biotherapeutics earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the company's share price in the next few days. View News Stories for Eleven Biotherapeutics.

Who are some of Eleven Biotherapeutics' key competitors?

What other stocks do shareholders of Eleven Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eleven Biotherapeutics investors own include Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Immunomedics (IMMU), SLS International (SLS), Dynavax Technologies (DVAX), Sesen Bio (SESN), Sophiris Bio (SPHS), TransEnterix (TRXC), iShares US Preferred Stock ETF (PFF) and Inovio Pharmaceuticals (INO).

Who are Eleven Biotherapeutics' key executives?

Eleven Biotherapeutics' management team includes the folowing people:
  • Mr. Stephen A. Hurly, Pres, CEO & Director (Age 50)
  • Dr. K. Christopher Garcia, Co-Founder and Member of Scientific Advisory Board
  • Dr. Gregory L. Verdine, Co-Founder (Age 59)
  • Dr. Karl Dane Wittrup Ph.D., Co-Founder and Member of Scientific Advisory Board
  • Dr. Reza Dana M.D., MPH,M.Sc, Founder and Member of Scientific Advisory Board

How do I buy shares of Eleven Biotherapeutics?

Shares of EBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Eleven Biotherapeutics' official website?

The official website for Eleven Biotherapeutics is http://www.elevenbio.com/.

How can I contact Eleven Biotherapeutics?

Eleven Biotherapeutics' mailing address is 215 FIRST STREET SUITE 400, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-9911 or via email at [email protected]


MarketBeat Community Rating for Eleven Biotherapeutics (NASDAQ EBIO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  156 (Vote Outperform)
Underperform Votes:  172 (Vote Underperform)
Total Votes:  328
MarketBeat's community ratings are surveys of what our community members think about Eleven Biotherapeutics and other stocks. Vote "Outperform" if you believe EBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Featured Article: Correction

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel